SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Common Stock Repurchased

Cash spent buying back the company's own shares.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Common Stock Repurchased · Q3 FY2026 · quarter ended Sep 2026

Common stock repurchased outflow grows to $0

Q3 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How SLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
SLS Competitors
Common Stock Repurchased for SLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥9.04M CNY—-30.4%1.6%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$238K USD-0.8%—0.7%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$177K USD——1.5%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
INCYIncyte CorporationLTM Jun 2026$0 USD+100.0%—0.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$0 USD——0.0%
IMNMImmunome, Inc.LTM Sep 2026$0 USD———
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 USD——0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$0 USD+100.0%—0.0%
MGNXMacroGenics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SLS) —+100.0%-30.4%0.0%

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Depreciation & Amortization1.27M457K37.87M31.51M0
Deferred Income Tax(239K)(457K)000
Stock-Based Compensation1.01M1.73M1.39M1.56M1.96M
Change in Working Capital(7.62M)5.64M3.35M(6.65M)(4.08M)
Accounts Receivables00000
Inventory00000
Accounts Payables(2.51M)1.21M2.3M(2.14M)(535K)
Other Working Capital(5.1M)4.43M1.04M(4.51M)(3.54M)
Other Non-Cash Items248K10.13M(36.67M)(30.95M)597K
Operating Cash Flow(26.02M)(23.81M)(31.41M)(35.4M)(28.39M)
Capital Expenditures0(4.5M)(5.5M)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(4.5M)(5.5M)00
Debt Repayment00000
Common Stock Issued9.01M23.99M22.23M46.16M86.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.07M85K90K594K(527K)
Financing Cash Flow12.07M24.08M22.32M46.76M86.3M
Effect of Forex Changes00000
Net Change in Cash(13.95M)(4.23M)(14.6M)11.36M57.91M
Free Cash Flow(26.02M)(28.31M)(36.91M)(35.4M)(28.39M)

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.